|
Effects of whole-brain radiotherapy, stereotactic ablation radiotherapy, and combined radiotherapy on brain metastases
|
Y. Luo   , X. Huang , L. Zhou , J. Chen |
| Department of Radiation Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People’s Republic of China , zhouliya1988@126.com |
|
|
Abstract: (1076 Views) |
Background: To investigate the effects of different radiotherapy regimens on the prognosis of patients with brain metastases. Materials and Methods: Patients with brain metastases undergoing radiotherapy from January 2016 to December 2020 were retrospectively analyzed. The patients were divided into a whole-brain radiotherapy (WBRT) group, stereotactic ablative radiotherapy (SABR) group, and WBRT+SABR group, and overall survival (OS) and progression-free survival (PFS) were analyzed. Results: Forty patients were candidates for the analysis, with a median age of 57.5 years and a median follow-up time of 27.4 months. The median OS and PFS were 35.7 and 13.5 months, respectively, and the median radiotherapy dose was 41.7 Gy. The median OS times for patients who received WBRT (n = 12), SABR (n = 21), and WBRT+SABR (n = 7) were 41.8, 70.6, and 56.8 months, respectively (p = 0.7). The median PFS times were 10.2 months, 34.3 months, and 25.9 months, respectively (p = 0.322). Subgroup analysis indicated that the OS times were 25.4 months after WBRT (n = 7), 79.1 months after SABR (n = 11), and 65.9 months after WBRT+SABR (n = 5) among patients with brain metastases from lung cancer (p = 0.028). The patients had PFS times of 7.1, 33.4, and 29.1 months after irradiation with WBRT, SABR, and combination therapy, respectively (p = 0.009). Conclusion: The three different radiotherapy regimens had no significant effects on the prognosis of patients with brain metastases. SBAR was superior to WBRT and WBRT+SABR with respect to the prognosis of patients with brain metastases from lung cancer. The sample size of this retrospective study was small; therefore, larger, prospective studies are needed. |
|
| Keywords: Brain metastases, malignant tumors, radiotherapy, whole-brain radiotherapy. |
|
|
Full-Text [PDF 558 kb]
(741 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Thiagarajan A and Yamada Y (2017) Radiobiology and radiotherapy of brain metastases. Clin Exp Metastasis, 34: 411-419. [ DOI:10.1007/s10585-017-9865-7] [ PMID] 2. Sacks P and Rahman M (2020) Epidemiology of brain metastases. Neurosurg Clin N Am, 31: 481-488. [ DOI:10.1016/j.nec.2020.06.001] [ PMID] 3. Kotecha R, Gondi V, Ahluwalia MS, et al. (2018) Recent advances in managing brain metastasis. F1000Res, 7: F1000 Faculty Rev-1772. [ DOI:10.12688/f1000research.15903.1] [ PMID] [ ] 4. Brown PD, Ahluwalia MS, Khan OH, et al. (2018) Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol, 36: 483-491. [ DOI:10.1200/JCO.2017.75.9589] [ PMID] [ ] 5. Tsao MN, Xu W, Wong RK, et al. (2018) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev, 1: CD003869. [ DOI:10.1002/14651858.CD003869.pub4] [ PMID] [ ] 6. Tadros S and Ray-Chaudhury A (2020) Pathological features of brain metastases. Neurosurg Clin N Am, 31: 549-564. [ DOI:10.1016/j.nec.2020.06.005] [ PMID] 7. Kocher M, Soffietti R, Abacioglu U, et al. (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol, 29: 134-141. [ DOI:10.1200/JCO.2010.30.1655] [ PMID] [ ] 8. Folkert MR and Timmerman RD (2017) Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Adv Drug Deliv Rev, 109: 3-14. [ DOI:10.1016/j.addr.2016.11.005] [ PMID] 9. Brun L, Dupic G, Chassin V, et al. (2021) Hypofractionated stereotactic radiotherapy for large brain metastases: Optimizing the dosimetric parameters. Cancer Radiother, 25: 1-7. [ DOI:10.1016/j.canrad.2020.04.011] [ PMID] 10. Makhlin I and Fox K (2020) Oligometastatic breast cancer: Is This a Curable Entity? A Contemporary Review of the Literature. Curr Oncol Rep, 22: 15. [ DOI:10.1007/s11912-020-0867-2] [ PMID] [ ] 11. Pagani O, Senkus E, Wood W, et al. (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst, 102: 456-463. [ DOI:10.1093/jnci/djq029] [ PMID] [ ] 12. Weykamp F, König L, Seidensaal K, et al. (2020) Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol, 10: 987. [ DOI:10.3389/fonc.2020.00987] [ PMID] [ ] 13. Dumont Lecomte D, Lequesne J, Geffrelot J, et al. (2019) Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions. Cancer Radiother, 23: 860-866. [ DOI:10.1016/j.canrad.2019.06.012] [ PMID] 14. Al-Shafa F, Arifin AJ, Rodrigues GB, et al. (2019) A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where Will the Evidence Lead? Front Oncol, 9: 543. [ DOI:10.3389/fonc.2019.00543] [ PMID] [ ] 15. Fogarty GB, Hong A, Gondi V, et al. (2016) Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer, 16: 372. [ DOI:10.1186/s12885-016-2433-8] [ PMID] [ ] 16. Hanna GG, Murray L, Patel R, et al. (2018) UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol), 30: 5-14.
https://doi.org/10.1016/j.clon.2017.09.007 [ DOI:10.1016/j.clon.2018.03.012] [ PMID] 17. Chang BK and Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol, 30: 637-644. [ DOI:10.1097/COC.0b013e3180ca7cb1] [ PMID] 18. Moravan MJ, Fecci PE, Anders CK, et al. (2020) Current multidisciplinary management of brain metastases. Cancer, 126: 1390-1406. [ DOI:10.1002/cncr.32714] [ PMID] 19. Brown PD, Ballman KV, Cerhan JH, et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 18: 1049-1060. [ DOI:10.1016/S1470-2045(17)30441-2] [ PMID] 20. Aoyama H, Shirato H, Tago M, et al. (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA, 295: 2483-2491. [ DOI:10.1001/jama.295.21.2483] [ PMID] 21. Qu XM, Chen Y, Zaric GS, et al. (2021) Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial. Int J Radiat Oncol Biol Phys, 109: 1176-1184. [ DOI:10.1016/j.ijrobp.2020.12.001] [ PMID] 22. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study - PubMed. https://pubmed.ncbi.nlm.nih.gov/24621620/. Accessed 13 Nov 2021. 23. Rusthoven CG, Yamamoto M, Bernhardt D, et al. (2020) Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: The FIRE-SCLC cohort study. JAMA Oncol, 6: 1028-1037. [ DOI:10.1001/jamaoncol.2020.1271] [ PMID] [ ] 24. Palma DA, Olson R, Harrow S, et al. (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 19: 816. [ DOI:10.1186/s12885-019-5977-6] [ PMID] [ ] 25. Chao ST, Dad LK, Dawson LA, et al. (2020) ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. Am J Clin Oncol, 43: 545-552. [ DOI:10.1097/COC.0000000000000706] [ PMID] 26. Schiff D, Messersmith H, Brastianos PK, et al. (2022) Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. J Clin Oncol, 40: 2271-2276. [ DOI:10.1200/JCO.22.00333] [ PMID] 27. Gondi V, Bauman G, Bradfield L, et al. (2022) Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol, 12: 265-282. [ DOI:10.1016/j.prro.2022.02.003] [ PMID] 28. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline - PubMed. https://pubmed.ncbi.nlm.nih.gov/32222430/. Accessed 27 Aug 2022 29. Dm T, Kv B, Pd B, et al. (2020) Optimizing whole brain radiation therapy dose and fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). Int J radiat oncol biolo physics,
https://doi.org/10.1016/j.ijrobp.2019.10.024 [ DOI:10.1016/j.ijrobp.2019.10.024.] [ PMID] [ ] 30. Canadian Cancer Trials Group (2021) A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases. clinicaltrials.gov.
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Luo Y, Huang X, Zhou L, Chen J. Effects of whole-brain radiotherapy, stereotactic ablation radiotherapy, and combined radiotherapy on brain metastases. Int J Radiat Res 2023; 21 (2) :299-303 URL: http://ijrr.com/article-1-4765-en.html
|
